OssDsign® Spine Registry Study for Degenerative Disc Disease and Spinal Stenosis
This study, called "Propel," is looking at how well a product called OssDsign® Catalyst works in people who need spinal fusion surgery. OssDsign® Catalyst is a special bone void filler that helps bones grow together. You might be able to join if you are at least 21 years old, need spinal fusion surgery for conditions like degenerative disc disease or spinal stenosis, and your surgeon has decided OssDsign® Catalyst is the right choice for you. The main goal is to see how many people achieve bone fusion (when bones grow together) 12 months after their surgery. The study is currently recruiting up to 450 participants, but the status is unclear.
- Study design
- This is an observational study, meaning researchers will watch and collect information about your care. It aims to enroll 450 participants across up to 25 sites in the US.
- What's involved
- You would need to comply with the post-operative plan, attend required follow-up visits, and fill out forms.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 24 months (plus or minus 90 days) after their surgery.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
OssDsign® Spine Registry Study ("Propel")
At a glance
Conditions
Where it's being run
15 sites across 10 statesStudy leadership
- Melanie Marshall · STUDY_DIRECTOR · OssDsign
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Rate of bone fusion12 months ± 60 days post-operative examination
Assessment of the rate of bone fusion via Computerized Tomography (CT)/x-ray based on evidence of continuous bone bridging from the superior to the inferior vertebral body at the target level.